Navigation Links
New Innovation in Clubfoot Treatment

A new brace that maintains correction for clubfoot, a birth defect in which the foot is turned in toward the body, has shown better compliance and fewer complications than the traditional brace used to treat the condition.

Matthew B. Dobbs, M.D., associate professor of orthopedic surgery at the School of Medicine, designed the new dynamic brace, called the Dobbs brace, to allow active movement, preserve muscle strength in the foot and ankle and be less restrictive to the child than the traditional brace.

Dobbs tested the brace on 28 patients who had already received non-surgical treatment for their clubfeet at St. Louis Children's Hospital and St. Louis Shriners Hospital. Over a two- to three-year follow-up period, Dobbs and his colleagues found that the Dobbs brace is at least as effective as the traditional brace and resulted in better compliance by parents.

Dobbs first treated children with clubfoot deformity using the Ponseti method. The treatment, developed in the 1950s by Ignacio Ponseti, M.D., professor emeritus of orthopedics and rehabilitation at the University of Iowa, involves weekly casting and manipulation of the clubfoot soon after birth.

When done correctly, the Ponseti method greatly reduces the need for extensive surgery, which can contribute to painful and arthritic feet in adulthood. The children with clubfoot whom Ponseti treated with this method were likely to have normally functioning, pain-free, flexible feet in adulthood.

Traditionally, children who have been treated for clubfoot using the Ponseti method must wear a nighttime brace that turns their feet away from the body for three to four years following the initial casting treatment.

The brace has open-toed, high-top shoes attached to a shoulder-width fixed metal bar. Because of skin blistering and the brace's restriction of leg motion, many parents used the brace less than had been prescribed, which can a
'"/>




Page: 1 2 3

Related medicine news :

1. Biocon To Shift Focus On Innovation To Accelerate Growth
2. IIT Delhi To Display Its Technological Innovations In Open House
3. Innovation Needed In The Field Of Diagnostics: Nair
4. Blood Safety, Supply, and Innovations Addressed at Conference
5. Advances in Treatment of Cataracts
6. Recommendations for Treatment of Blood Pressue
7. Treatment for Menieres disease
8. Treatment for pre-menstrual syndrome is ineffective
9. Better Treatment for obesity
10. Gene Treatment for Heart Disease
11. More People Seeking Treatment for Depression
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Innovation Clubfoot Treatment

(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for
(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W
(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
Breaking Medicine News(10 mins):Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2
...CFS) has been associated with altered amounts of s...oencephalograph (EEG) activity and impaired sleep... journal SLEEP finds that CFS is also associated w...Roseanna Armitage, PhD, and colleagues at the Univ...
... not pose a risk of cancer; a Danish study conduct... has shown. Danish medical records were a... cancer, or brain cancer among the utility workers...bstantial evidence linking exposure to electro mag...
... have died in a hospital here in the month of Apri...ed from his post for not informing the state gove...s, however, put the number of infant deaths at the...sts conducted at the microbiology department of th...
...eed lift one out of depression. But its potential ...ognized . Now the U.S. Food and Drug Admin...tidepressant medications update the existing black...ring initial treatment, generally the first one to...
...Dakota is now infusing roasted sunflower seeds w...energy drinks , to provide players and other peopl... The product, which has been under developmen...e, lysine and ginseng are added. The 3.5-ounc...
...rchers, diabetes is fast becoming a common reason ...he Reproductive Medicine Research Group at Queen's... semen samples of 57 men who were diagnosed with D...such samples it was seen that diabetes brought abo...
Other Medicine News:Health News:Government Expels Superintendent for Not Informing Newborn Deaths 2Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 2Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 3Health News:Caffeinated Sunflower Seeds To Hit The Market 2Health News:Fertility Rates Felled By Diabetes 2
(Date:12/4/2009)MORRISTOWN, N.J., Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed
(Date:12/4/2009)RARITAN, N.J., Dec. 4 Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur
(Date:12/3/2009)SUNNYVALE, Calif., Dec. 3 Pharmacyclics, Inc. (Nasdaq: PCYC ), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune media
Breaking Medicine Technology:Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2US Oncology Reports Second Quarter Operating Results 53858 1US Oncology Reports Second Quarter Operating Results 53858 2US Oncology Reports Second Quarter Operating Results 53858 3US Oncology Reports Second Quarter Operating Results 53858 4US Oncology Reports Second Quarter Operating Results 53858 5US Oncology Reports Second Quarter Operating Results 53858 6US Oncology Reports Second Quarter Operating Results 53858 7US Oncology Reports Second Quarter Operating Results 53858 8US Oncology Reports Second Quarter Operating Results 53858 9US Oncology Reports Second Quarter Operating Results 53858 10US Oncology Reports Second Quarter Operating Results 53858 11US Oncology Reports Second Quarter Operating Results 53858 12US Oncology Reports Second Quarter Operating Results 53858 13US Oncology Reports Second Quarter Operating Results 53858 14US Oncology Reports Second Quarter Operating Results 53858 15US Oncology Reports Second Quarter Operating Results 53858 16US Oncology Reports Second Quarter Operating Results 53858 17US Oncology Reports Second Quarter Operating Results 53858 18US Oncology Reports Second Quarter Operating Results 53858 19US Oncology Reports Second Quarter Operating Results 53858 20US Oncology Reports Second Quarter Operating Results 53858 21US Oncology Reports Second Quarter Operating Results 53858 22US Oncology Reports Second Quarter Operating Results 53858 23US Oncology Reports Second Quarter Operating Results 53858 24US Oncology Reports Second Quarter Operating Results 53858 25Efforts by Blue Cross Blue Shield of Michigan Physician Practices Help Michigan Become a Leading Adopter of E prescribing 53856 1Efforts by Blue Cross Blue Shield of Michigan Physician Practices Help Michigan Become a Leading Adopter of E prescribing 53856 2Efforts by Blue Cross Blue Shield of Michigan Physician Practices Help Michigan Become a Leading Adopter of E prescribing 53856 3BD Adds Surveillance Capability to Infectious Disease Portfolio 53851 1BD Adds Surveillance Capability to Infectious Disease Portfolio 53851 2BD Adds Surveillance Capability to Infectious Disease Portfolio 53851 3
...o, a division of Merck KGaA, Darmstadt, Germany, t... develop and commercialize Ambrx,s ARX424 preclini...e sclerosis. ARX424 was created by Ambrx through ...ation technology, ReCODE(TM). , , This second col...vious agreement announced in 2007 to develop ARX20...
...ceuticals, Inc. (Nasdaq: MAPP ) announced today ...nit Dose Budesonide (UDB) for the potential,treatm...d that the clinical,trial did not meet its co-prim...es from baseline in nighttime and daytime composit..., when compared with placebo. Median,nebulization...
Other Medicine Technology:Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance 2Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance 3MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 2MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 3
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
Medicine Products: